about
CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes.Gene Expression Signature Differentiates Histology But Not Progression Status of Early-Stage NSCLC.Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications.The impact of immune responses on lung cancer and the development of new treatment modalities.The epidemiology of asbestos-related diseases.Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer.Core-shell magnetic nanoparticles display synergistic antibacterial effects against Pseudomonas aeruginosa and Staphylococcus aureus when combined with cathelicidin LL-37 or selected ceragenins.Fetal membranes as a source of stem cells.Validation for histology-driven diagnosis in non-small cell lung cancer using hsa-miR-205 and hsa-miR-21 expression by two different normalization strategies.Interleukin-33 as a New Marker of Pulmonary Sarcoidosis.Prognostic significance of Notch ligands in patients with non-small cell lung cancerNew monoallelic combination of KRAS gene mutations in codons 12 and 13 in the lung adenocarcinoma.Chronic high-protein diet induces oxidative stress and alters the salivary gland function in rats.Lysosomal Exoglycosidase Profile and Secretory Function in the Salivary Glands of Rats with Streptozotocin-Induced Diabetes.Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer.Clinical Significance of HMGB-1 and TGF-β Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer.Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer.Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancerp53 gene mutation and protein expression in operable non-small cell lung cancer in PolandPreoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancerPrognostic value of serum p53 antibodies in patients with resected non-small cell lung cancerEffect of endurance training on the phospholipid content of skeletal muscles in the ratOsteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis: A Bronchoalveolar Lavage StudyTypes and localisation of p53 gene mutations: a report on 332 non-small cell lung cancer patientsReport from the first meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona-Bialystok-Heidelberg'. Thoraxklinik Heidelberg, Germany, July 25, 2001Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancersTumor necrosis factor-alpha and its receptors in epithelial ovarian cancerCirculating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancerMutations in the KRAS gene in ovarian tumors
P50
Q33562564-9E166D6D-CF50-4F67-A671-E71DDF58E5E9Q33611881-CCCE1ACC-36BD-4A2A-9FAD-305DBAA08B07Q34296852-CB090580-3CBD-4308-A0B0-D4A7E15434F1Q34447434-EDB8C965-30EF-4376-A8A0-A33A2FD030DDQ35839830-F5B95EC1-5898-4076-9654-16B5BCB07C39Q36336498-AC5A5FFE-EC12-4EED-B767-79604AA40CA2Q37361845-5D42AEF5-D940-43EB-BFD6-8B9086065A34Q38170343-FE82AF9A-4B3E-41B5-A9AF-FA7E054869D0Q40603527-B323A559-03ED-437D-B890-2783AAB89F4BQ40891494-D113CD92-B645-4CD8-9923-C14511EFC68DQ41824016-5C8C642D-9C22-4836-8848-46E5172D7730Q45173562-74E517B3-8252-40C7-B0A9-7FF3F1A16182Q46304456-0D8D81D1-6274-41F1-B7AD-FEA8C3F9D044Q49724222-BFCDA8AA-980E-4888-A335-C8B5D488EEBCQ51543550-43703AF2-26E0-4C8D-8FCD-EEA395750F00Q53589652-0DCF5038-E22C-4F1D-B1D3-1DAD5B54FCCFQ54977595-A8F25D31-7789-4D31-963C-8B39E5B1C7C7Q59901766-EE8CE72D-6A7A-43E4-B3AB-BA86222335F5Q59901788-E814C342-A790-44AE-B993-3A2CE984E777Q59901802-EFB9870F-2EA7-4A71-BB61-7F57DE3C372FQ59901804-567B2018-3788-4DB4-9147-171E16E3655FQ62034378-D17A0FC9-87F1-4869-9507-9D57B710DA71Q62588837-3DAC16CB-2DF0-4731-B16B-84CE0F46376DQ77224984-774574E2-2E35-424D-89BB-43D2BE868063Q77947383-50921286-1B91-46AF-A82B-7F5ABE00975CQ82562900-39A9DA27-2504-4F83-B560-AAA30B115D4FQ84133426-A7564220-9D2B-44B1-ABE7-ED4657A246DCQ84978415-EDD5C2F5-9F1C-404C-9C15-C595192A84C6Q85054904-45D4CDED-B8EE-40F1-9942-C044BE4E923F
P50
description
Polish researcher
@en
Pools onderzoekster
@nl
polska naukowiec
@pl
taighdeoir Polannach
@ga
name
Wiesława Niklińska
@ast
Wiesława Niklińska
@ca
Wiesława Niklińska
@cs
Wiesława Niklińska
@de
Wiesława Niklińska
@en
Wiesława Niklińska
@es
Wiesława Niklińska
@fr
Wiesława Niklińska
@ga
Wiesława Niklińska
@gl
Wiesława Niklińska
@hr
type
label
Wiesława Niklińska
@ast
Wiesława Niklińska
@ca
Wiesława Niklińska
@cs
Wiesława Niklińska
@de
Wiesława Niklińska
@en
Wiesława Niklińska
@es
Wiesława Niklińska
@fr
Wiesława Niklińska
@ga
Wiesława Niklińska
@gl
Wiesława Niklińska
@hr
altLabel
Wiesława Ewa Niklińska
@pl
prefLabel
Wiesława Niklińska
@ast
Wiesława Niklińska
@ca
Wiesława Niklińska
@cs
Wiesława Niklińska
@de
Wiesława Niklińska
@en
Wiesława Niklińska
@es
Wiesława Niklińska
@fr
Wiesława Niklińska
@ga
Wiesława Niklińska
@gl
Wiesława Niklińska
@hr
P106
P1153
6701907294
P1412
P1559
Wiesława Niklińska
@pl
P21
P214
52152682489223310202
P27
P31
P3124
P496
0000-0002-4587-1323
P7859
viaf-52152682489223310202